The potential role of sodium glucose co‐transporter 2 inhibitors in the early treatment of type 2 diabetes mellitus

BACKGROUND: Sodium glucose co‐transporter 2 (SGLT2) inhibitors are a new class of pharmacologic agents developed for the treatment of type 2 diabetes mellitus (T2DM). Their unique mechanism of action is independent of pancreatic beta‐cell function or the degree of insulin resistance, giving these ag...

Descripción completa

Detalles Bibliográficos
Autor principal: Brunton, S. A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4758393/
https://www.ncbi.nlm.nih.gov/pubmed/26147213
http://dx.doi.org/10.1111/ijcp.12675
_version_ 1782416600688754688
author Brunton, S. A.
author_facet Brunton, S. A.
author_sort Brunton, S. A.
collection PubMed
description BACKGROUND: Sodium glucose co‐transporter 2 (SGLT2) inhibitors are a new class of pharmacologic agents developed for the treatment of type 2 diabetes mellitus (T2DM). Their unique mechanism of action is independent of pancreatic beta‐cell function or the degree of insulin resistance, giving these agents the potential for use in combination with any of the existing classes of glucose‐lowering agents, including insulin. This makes SGLT2 inhibitors an option for patients with long‐standing T2DM, but they also have a promising role for early intervention in T2DM, and that role is explored in this review. METHODS: A literature search was performed to identify relevant English language articles relating to SGLT2 inhibitors, particularly dapagliflozin, canagliflozin and empagliflozin. RESULTS: Clinical trials of dapagliflozin, canagliflozin and empagliflozin, given as monotherapy or in combination with other glucose‐lowering agents, reported clinically significant improvements in glycaemic control, body weight and systolic blood pressure. SGLT2 inhibitors were well tolerated and had a generally favourable safety profile. Few serious adverse events have been reported to date. The frequency of hypoglycaemic events was low, similar to that of placebo, and the choice of co‐administered glucose‐lowering agent was the major determinant of hypoglycaemic risk. Increased genital and urinary tract infections were consistently reported with SGLT2 inhibitors. CONCLUSIONS: SGLT2 inhibitors, with their unique insulin‐independent mode of action, could have a significant impact on the early management of T2DM, by addressing some of the specific risk factors associated with this disease. SGLT2 inhibitors induce beneficial changes in a number of cardiovascular risk factors, such as lowering blood pressure and body weight, in addition to improved glycaemic control, although information on clinical cardiovascular outcomes is currently limited.
format Online
Article
Text
id pubmed-4758393
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-47583932016-02-29 The potential role of sodium glucose co‐transporter 2 inhibitors in the early treatment of type 2 diabetes mellitus Brunton, S. A. Int J Clin Pract Endocrinology & Metabolism BACKGROUND: Sodium glucose co‐transporter 2 (SGLT2) inhibitors are a new class of pharmacologic agents developed for the treatment of type 2 diabetes mellitus (T2DM). Their unique mechanism of action is independent of pancreatic beta‐cell function or the degree of insulin resistance, giving these agents the potential for use in combination with any of the existing classes of glucose‐lowering agents, including insulin. This makes SGLT2 inhibitors an option for patients with long‐standing T2DM, but they also have a promising role for early intervention in T2DM, and that role is explored in this review. METHODS: A literature search was performed to identify relevant English language articles relating to SGLT2 inhibitors, particularly dapagliflozin, canagliflozin and empagliflozin. RESULTS: Clinical trials of dapagliflozin, canagliflozin and empagliflozin, given as monotherapy or in combination with other glucose‐lowering agents, reported clinically significant improvements in glycaemic control, body weight and systolic blood pressure. SGLT2 inhibitors were well tolerated and had a generally favourable safety profile. Few serious adverse events have been reported to date. The frequency of hypoglycaemic events was low, similar to that of placebo, and the choice of co‐administered glucose‐lowering agent was the major determinant of hypoglycaemic risk. Increased genital and urinary tract infections were consistently reported with SGLT2 inhibitors. CONCLUSIONS: SGLT2 inhibitors, with their unique insulin‐independent mode of action, could have a significant impact on the early management of T2DM, by addressing some of the specific risk factors associated with this disease. SGLT2 inhibitors induce beneficial changes in a number of cardiovascular risk factors, such as lowering blood pressure and body weight, in addition to improved glycaemic control, although information on clinical cardiovascular outcomes is currently limited. John Wiley and Sons Inc. 2015-07-05 2015-10 /pmc/articles/PMC4758393/ /pubmed/26147213 http://dx.doi.org/10.1111/ijcp.12675 Text en © 2015 The Authors. International Journal of Clinical Practice Published by John Wiley & Sons Ltd. This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs (http://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Endocrinology & Metabolism
Brunton, S. A.
The potential role of sodium glucose co‐transporter 2 inhibitors in the early treatment of type 2 diabetes mellitus
title The potential role of sodium glucose co‐transporter 2 inhibitors in the early treatment of type 2 diabetes mellitus
title_full The potential role of sodium glucose co‐transporter 2 inhibitors in the early treatment of type 2 diabetes mellitus
title_fullStr The potential role of sodium glucose co‐transporter 2 inhibitors in the early treatment of type 2 diabetes mellitus
title_full_unstemmed The potential role of sodium glucose co‐transporter 2 inhibitors in the early treatment of type 2 diabetes mellitus
title_short The potential role of sodium glucose co‐transporter 2 inhibitors in the early treatment of type 2 diabetes mellitus
title_sort potential role of sodium glucose co‐transporter 2 inhibitors in the early treatment of type 2 diabetes mellitus
topic Endocrinology & Metabolism
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4758393/
https://www.ncbi.nlm.nih.gov/pubmed/26147213
http://dx.doi.org/10.1111/ijcp.12675
work_keys_str_mv AT bruntonsa thepotentialroleofsodiumglucosecotransporter2inhibitorsintheearlytreatmentoftype2diabetesmellitus
AT bruntonsa potentialroleofsodiumglucosecotransporter2inhibitorsintheearlytreatmentoftype2diabetesmellitus